Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients - PubMed (original) (raw)
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
June-Chul Lee et al. J Immunol. 2004.
Abstract
NK cell function in cancer patients is severely impaired, but the mechanism underlying this impairment is not clearly understood. In this study we show evidence that TGF-beta1 secreted by tumors is responsible for the poor NK lytic activity via down-regulating an NK-activating receptor, NKG2D. The plasma level of TGF-beta1 in human lung cancer or colorectal cancer patients was elevated compared with that in normal volunteers, and this elevation was inversely correlated with surface expression of NKG2D on NK cells in these patients. Incubation of NK cells with plasma obtained from cancer patients specifically down-modulated surface NKG2D expression, whereas addition of neutralizing anti-TGF-beta1 mAbs completely restored surface NKG2D expression. Likewise, incubation of NK cells and lymphokine-activated killer cells with TGF-beta1 resulted in dramatic reduction of surface NKG2D expression associated with impaired NK cytotoxicity. Modulation of NKG2D by TGF-beta1 was specific, as expression of other NK receptors, CD94/NKG2A, CD44, CD16, 2B4, or CD56, was not affected by TGF-beta1. Impaired NK cytotoxicity by TGF-beta1 was not due to alteration of lytic moieties, such as perforin or Fas, or apoptotic pathway, but, rather, appeared to be due to lack of NKG2D expression. Taken together, our data suggest that impaired NK function in cancer patients can be attributed to down-modulation of activating receptors, such as NKG2D, via secretion of TGF-beta1.
Similar articles
- Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, Chatterjee SK. Dasgupta S, et al. J Immunol. 2005 Oct 15;175(8):5541-50. doi: 10.4049/jimmunol.175.8.5541. J Immunol. 2005. PMID: 16210663 - A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1.
Lee JC, Lee KM, Ahn YO, Suh B, Heo DS. Lee JC, et al. Tumori. 2011 May-Jun;97(3):350-7. doi: 10.1177/030089161109700316. Tumori. 2011. PMID: 21789015 - Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
Lazarova M, Steinle A. Lazarova M, et al. Front Immunol. 2019 Nov 15;10:2689. doi: 10.3389/fimmu.2019.02689. eCollection 2019. Front Immunol. 2019. PMID: 31803194 Free PMC article. Review. - Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy.
Touboul R, Zaravinos A, Bonavida B. Touboul R, et al. Crit Rev Immunol. 2021;41(2):45-76. doi: 10.1615/CritRevImmunol.2021037186. Crit Rev Immunol. 2021. PMID: 34348002 Review.
Cited by
- The paradoxical role of transforming growth factor-β in controlling oral squamous cell carcinoma development.
Peng R, Huang Y, Huang P, Liu L, Cheng L, Peng X. Peng R, et al. Cancer Biomark. 2024;40(3-4):241-250. doi: 10.3233/CBM-230354. Cancer Biomark. 2024. PMID: 39213051 Free PMC article. Review. - The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?
Franks ML, An JH, Leavenworth JW. Franks ML, et al. Vaccines (Basel). 2024 Jun 28;12(7):721. doi: 10.3390/vaccines12070721. Vaccines (Basel). 2024. PMID: 39066359 Free PMC article. Review. - HPK1 Dysregulation-Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression.
Choi WS, Kwon HJ, Yi E, Lee H, Kim JM, Park HJ, Choi EJ, Choi ME, Sung YH, Won CH, Sung CO, Kim HS. Choi WS, et al. Adv Sci (Weinh). 2024 Aug;11(29):e2400920. doi: 10.1002/advs.202400920. Epub 2024 Jun 3. Adv Sci (Weinh). 2024. PMID: 38828677 Free PMC article. - Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease.
Fernández-Soto D, García-Jiménez ÁF, Casasnovas JM, Valés-Gómez M, Reyburn HT. Fernández-Soto D, et al. Front Immunol. 2024 Feb 12;15:1273942. doi: 10.3389/fimmu.2024.1273942. eCollection 2024. Front Immunol. 2024. PMID: 38410511 Free PMC article. - Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.
Poveda-Garavito N, Combita AL. Poveda-Garavito N, et al. Front Immunol. 2024 Jan 17;14:1325255. doi: 10.3389/fimmu.2023.1325255. eCollection 2023. Front Immunol. 2024. PMID: 38299154 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous